230 related articles for article (PubMed ID: 20361239)
21. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
Wang A; Stout CD; Zhang Q; Johnson EF
J Biol Chem; 2015 Feb; 290(8):5092-5104. PubMed ID: 25555909
[TBL] [Abstract][Full Text] [Related]
22. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
23. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.
McLaughlin LA; Paine MJ; Kemp CA; Maréchal JD; Flanagan JU; Ward CJ; Sutcliffe MJ; Roberts GC; Wolf CR
J Biol Chem; 2005 Nov; 280(46):38617-24. PubMed ID: 16162505
[TBL] [Abstract][Full Text] [Related]
24. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.
Lewis DF; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1997 Apr; 27(4):319-39. PubMed ID: 9149373
[TBL] [Abstract][Full Text] [Related]
25. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
26. The molecular basis of CYP2D6-mediated N-dealkylation: balance between metabolic clearance routes and enzyme inhibition.
Bonn B; Masimirembwa CM; Aristei Y; Zamora I
Drug Metab Dispos; 2008 Nov; 36(11):2199-210. PubMed ID: 18725510
[TBL] [Abstract][Full Text] [Related]
27. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
28. Impact of plasticity and flexibility on docking results for cytochrome P450 2D6: a combined approach of molecular dynamics and ligand docking.
Hritz J; de Ruiter A; Oostenbrink C
J Med Chem; 2008 Dec; 51(23):7469-77. PubMed ID: 18998665
[TBL] [Abstract][Full Text] [Related]
29. Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4.
De Rienzo F; Fanelli F; Menziani MC; De Benedetti PG
J Comput Aided Mol Des; 2000 Jan; 14(1):93-116. PubMed ID: 10702928
[TBL] [Abstract][Full Text] [Related]
30. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.
Ellis SW; Rowland K; Ackland MJ; Rekka E; Simula AP; Lennard MS; Wolf CR; Tucker GT
Biochem J; 1996 Jun; 316 ( Pt 2)(Pt 2):647-54. PubMed ID: 8687412
[TBL] [Abstract][Full Text] [Related]
31. Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.
Smith G; Modi S; Pillai I; Lian LY; Sutcliffe MJ; Pritchard MP; Friedberg T; Roberts GC; Wolf CR
Biochem J; 1998 May; 331 ( Pt 3)(Pt 3):783-92. PubMed ID: 9560305
[TBL] [Abstract][Full Text] [Related]
32. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
33. Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6.
Haji-Momenian S; Rieger JM; Macdonald TL; Brown ML
Bioorg Med Chem; 2003 Dec; 11(24):5545-54. PubMed ID: 14642599
[TBL] [Abstract][Full Text] [Related]
34. Human cytochrome P450 enzymes bind drugs and other substrates mainly through conformational-selection modes.
Guengerich FP; Wilkey CJ; Phan TTN
J Biol Chem; 2019 Jul; 294(28):10928-10941. PubMed ID: 31147443
[TBL] [Abstract][Full Text] [Related]
35. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
[TBL] [Abstract][Full Text] [Related]
36. Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking.
de Graaf C; Oostenbrink C; Keizers PH; van der Wijst T; Jongejan A; Vermeulen NP
J Med Chem; 2006 Apr; 49(8):2417-30. PubMed ID: 16610785
[TBL] [Abstract][Full Text] [Related]
37. Tryptophan-75 Is a Low-Energy Channel-Gating Residue that Facilitates Substrate Egress/Access in Cytochrome P450 2D6.
McCarty KD; Ratliff SA; Furge KA; Furge LL
Drug Metab Dispos; 2021 Mar; 49(3):179-187. PubMed ID: 33376147
[TBL] [Abstract][Full Text] [Related]
38. Prediction of drug metabolism: the case of cytochrome P450 2D6.
Vermeulen NP
Curr Top Med Chem; 2003; 3(11):1227-39. PubMed ID: 12769702
[TBL] [Abstract][Full Text] [Related]
39. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.
de Groot MJ; Ackland MJ; Horne VA; Alex AA; Jones BC
J Med Chem; 1999 May; 42(9):1515-24. PubMed ID: 10229622
[TBL] [Abstract][Full Text] [Related]
40. Computational Analysis of Physicochemical Factors Driving CYP2D6 Ligand Interaction.
Olubiyi OO; Olagunju MO; Obisesan AO
Curr Comput Aided Drug Des; 2017; 13(1):39-47. PubMed ID: 27632988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
